



Deposited via The University of Leeds.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/216164/>

Version: Supplemental Material

Article:

Mukherjee, S., Qi, C., Shaw, R. et al. (2024) Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. *European Journal of Cancer*, 209. 114236. ISSN: 0959-8049

<https://doi.org/10.1016/j.ejca.2024.114236>

© 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. This is an author produced version of an article published in *European Journal of Cancer* made available under the CC-BY-NC-ND 4.0 license (<http://creativecommons.org/licenses/by-nc-nd/4.0>) in accordance with the publisher's self-archiving policy.

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Highlights (3-5 bullet points, max 85 characters per point)

- Nelfinavir and high-dose chemoradiotherapy (CRT) are well tolerated
- No improvement in overall survival is seen with high versus standard dose CRT
- Nelfinavir does not improve outcomes when used concurrent with CRT
- CRT dose escalation may improve local tumour control
- Health-related quality of life is not impacted by CRT dose escalation or nelfinavir